Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

ENETS Abstract Search

#3458 Post-PRRT imaging: Which scans to make and what to look for

Introduction: Post-PRRT imaging often focuses on dosimetry but seldom on its clinical utility.

Conference:

Presenting Author: Aalbersberg E

Authors: Aalbersberg E, Huizing D, Tesselaar M, Stokkel M, Versleijen M,

Keywords: PRRT,

#1700 Distribution of 68Ga-HA-DOTATATE and 68Ga-DOTATATE in 343 Patients: Not the Same after All

Introduction: For the detection of neuroendocrine tumors, 68Ga-DOTATATE was developed but its use is restricted. This led to the development of 68Ga-HA-DOTATATE. In the literature, they are described as having comparable distributions.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Aalbersberg E, Stokkel M,

Keywords: HA-DOTATATE,

#1341 Interim Results on the Influence of Lanreotide on Uptake of [68Ga]-DOTATATE in Patients with Metastatic or Unresectable NET: No Evidence for Discontinuation of Lanreotide before [68Ga]-DOTATATE PET/CT

Introduction: Somatostatin receptor imaging with [68Ga]-DOTATATE PET/CT has become common practice in patients with NET. Current guidelines recommend discontinuing treatment with SSAs before obtaining a [68Ga]-DOTATATE PET/CT scan. The assumption is that unlabeled somatostatin may lower the detectability of lesions.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Aalbersberg E, Saveur L, Tesselaar M, Stokkel M,

Keywords: DOTATATE,